https://www.medlink.com/news/from-blood-sugar-to-brain-relief-glp-1-therapy-slashes-migraine-frequency MedLink proudly congratulates Editor-in-Chief, Dr. Steven Lewis, on his election as the next President of the World Federation of Neurology. Log In Sign Up for a Free Account * Clinical Categories + Developmental Malformations + Epilepsy & Seizures + General Child Neurology + General Neurology + Headache & Pain + Infectious Disorders + Movement Disorders + Neuro-Oncology + Neuro-Ophthalmology & Neuro-Otology + Neurobehavioral & Cognitive Disorders + Neurogenetic Disorders + Neuroimmunology + Neuromuscular Disorders + Neuropharmacology & Neurotherapeutics + Neurotoxicology + Peripheral Neuropathies + Perspectives + Sleep Disorders + Stroke & Vascular Disorders + Developmental Malformations Epilepsy & Seizures + General Child Neurology General Neurology + Headache & Pain Infectious Disorders + Movement Disorders Neuro-Oncology + Neuro-Ophthalmology & Neuro-Otology Neurobehavioral & Cognitive Disorders + Neurogenetic Disorders Neuroimmunology + Neuromuscular Disorders Neuropharmacology & Neurotherapeutics + Neurotoxicology Peripheral Neuropathies + Perspectives Sleep Disorders + Stroke & Vascular Disorders * Articles * Handouts * News & More + LatestNews releases, announcements, interviews and other supplemental content of neurologic interest + BlogExplore a variety of blog posts on neurologic topics from historical innovations to current practice issues and career insights + Events CalendarDiscover upcoming events in neurology and neuroscience + Featured ContributorsMeet some of the expert physicians who serve as MedLink Neurology authors and editors + News ReleasesStay informed with the latest news in neurology and neuroscience + PodcastsListen to clinical cases and topical reviews in neurology + Recently PublishedView lists of new and recently updated articles * About MedLink + Why MedLink + Editorial Board + Contributors + Contact Us + About MedLink CME MedLink(r), LLC 3525 Del Mar Heights Rd, Ste 304 San Diego, CA 92130-2122 Toll Free (U.S. + Canada): 800-452-2400 US Number: +1-619-640-4660 Support: service@medlink.com Editor: editor@medlink.com ISSN: 2831-9125 * Plans & Pricing * Toll Free (U.S. + Canada): 800-452-2400 US Number: +1-619-640-4660 Support: service@medlink.com Editor: editor@medlink.com ISSN: 2831-9125 Log In Sign Up for a Free Account Sign Up for a Free Account Worddefinition At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas. Go to Pubmed * News Releases * * + + + 06.24.2025 From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency Notice: News releases are not subject to review by MedLink Neurology 's Editorial Board. Researchers at the Headache Centre of the University of Naples "Federico II" gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine (defined as 15 or more headache days per month). Patients reported an average of 11 fewer headache days per month, while disability scores on the Migraine Disability Assessment Test dropped by 35 points, indicating a clinically meaningful improvement in work, study, and social functioning. GLP-1 agonists have gained recent widespread attention, reshaping treatment approaches for several diseases, including diabetes and cardiovascular disease.^2 In the treatment of type 2 diabetes, liraglutide helps lower blood sugar levels and reduce body weight by suppressing appetite and reducing energy intake.^3,4,5 Importantly, while participants' body mass index declined slightly (from 34.01 to 33.65), this change was not statistically significant. An analysis of covariance confirmed that BMI reduction had no effect on headache frequency, strengthening the hypothesis that pressure modulation, not weight loss, drives the benefit. "Most patients felt better within the first two weeks and reported quality of life improved significantly", said lead researcher Dr Simone Braca. "The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant." Patients were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out idiopathic intracranial hypertension (IIH) as a confounding factor. Growing evidence closely links subtle increases in intracranial pressure to migraine attacks.^6 GLP-1-receptor agonists, such as liraglutide, reduce cerebrospinal fluid secretion and have already proved effective in treating IIH.^7 Therefore, building on these observations, Dr Braca and colleagues hypothesised that exploiting the same mechanism of action might ultimately dampen cortical and trigeminal sensitisation that underlie migraine. "We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide", Dr Braca explained. "That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway." Mild gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants but did not lead to treatment discontinuation. Following this exploratory 12-week pilot study, a randomised, double-blind trial with direct or indirect intracranial pressure measurement is now being planned by the same research team in Naples, led by Professor Roberto De Simone. "We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects", Dr Braca noted. If confirmed, GLP-1-receptor agonists could offer a new treatment option for the estimated one in seven people worldwide who live with migraine,^8 particularly those who do not respond to current preventives. Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology. References: 1. Braca S, Russo C, et al. GLP-1R Agonists for the Treatment of Migraine: A Pilot Prospective Observational Study. Abstract A-25-13975. Presented at the 11^th EAN Congress (Helsinki, Finland). 2. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9(1):234. 3. Lin CH, Shao L, Zhang YM, et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother 2020;21(3):275-85. 4. Moon S, Lee J, Chung HS, et al. Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials. Endocrinol Metab (Seoul) 2021;36(3):647-60. 5. Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2016;55(6):657-72. 6. De Simone R, Sansone M, Russo C, Miele A, Stornaiuolo A, Braca S. The putative role of trigemino-vascular system in brain perfusion homeostasis and the significance of the migraine attack. Neurol Sci 2022;43(9):5665-72. 7. Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain 2023;146(5):1821-30. 8. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain 2020;21(1):137. Source: News Release European Academy of Neurology June 20, 2025 Questions or Comment? MedLink(r), LLC 3525 Del Mar Heights Rd, Ste 304 San Diego, CA 92130-2122 Toll Free (U.S. + Canada): 800-452-2400 US Number: +1-619-640-4660 Support: service@medlink.com Editor: editor@medlink.com ISSN: 2831-9125 Related Articles * Hemiplegic migraine * Vestibular migraine * Migraine treatment * Migraine: clinical aspects Clinical Categories * Headache & Pain Related Articles * Neurobehavioral & Cognitive Disorders Attention deficit hyperactivity disorder May. 08, 2025 * General Neurology Pseudobulbar affect Jul. 29, 2025 * Neuropharmacology & Neurotherapeutics Serotonin syndrome Oct. 21, 2025 * Neuro-Ophthalmology & Neuro-Otology Amblyopia Mar. 06, 2025 * Neuro-Oncology Paraneoplastic retinopathy Aug. 01, 2025 * Epilepsy & Seizures Myoclonic epilepsy in infancy Dec. 25, 2024 * Sleep Disorders Sleep and epilepsy Sep. 01, 2025 * Movement Disorders Movement disorders associated with autoimmune encephalitis Apr. 24, 2025 Filter by Save * Terms and Conditions * Privacy Notice * Citing MedLink * CME Accreditation Information * Contribute to MedLink Neurology * Glossary Copyright(c) 2001-2025 MedLink(r), LLC. All rights reserved. MedLink(r), LLC 3525 Del Mar Heights Rd, Ste 304 San Diego, CA 92130-2122 Toll Free (U.S. + Canada): 800-452-2400 US Number: +1-619-640-4660 Support: service@medlink.com Editor: editor@medlink.com ISSN: 2831-9125